Melissa Lumish MD (@lumishmelissa) 's Twitter Profile
Melissa Lumish MD

@lumishmelissa

GI oncologist UH Seidman Cancer Center @caseccc @UHHosp. Interested in Early Onset GI Cancers and Microbiome | Previously @MSKCancerCenter | Former @mghmedres

ID: 1257065389583892489

calendar_today03-05-2020 21:52:11

37 Tweet

487 Followers

308 Following

Karuna Ganesh (@karunamdphd) 's Twitter Profile Photo

Super excited to share the first preprint from Karuna Ganesh Lab! An amazing collaboration with dana_peer, led by the phenomenal andrew moorman @f_cambuli and Ellie Benitez Memorial Sloan Kettering Cancer Center. Progressive #Plasticity during #ColorectalCancer #Metastasis. biorxiv.org/content/10.110…

Melissa Lumish MD (@lumishmelissa) 's Twitter Profile Photo

Important work by colleague Sakti Chakrabarti, MD outlining real world and clinical trial data that supports the use of neoadjuvant PD-1 blockade for locally advanced MSI-H tumors.

Rojano Kashani (@kashanirojano) 's Twitter Profile Photo

Thrilled to see Lauren Henke, MD, MSCI representing our RadOncUH team onstage at #ASTRO23 to announce HyperSight on TrueBeam with Varian (510K pending). This first-in-the-world patient imaging clinical trial & new tech is just the start of the innovations to come ⚡️

Thrilled to see <a href="/lauren_henke/">Lauren Henke, MD, MSCI</a> representing our <a href="/RadOncUH/">RadOncUH</a> team onstage at #ASTRO23 to announce HyperSight on TrueBeam with <a href="/VarianMedSys/">Varian</a> (510K pending). This first-in-the-world patient imaging clinical trial &amp; new tech is just the start of the innovations to come ⚡️
ACS Journal Cancer (@journalcancer) 's Twitter Profile Photo

Just published! "Top advances of the year: Ovarian Cancer" by Dr. Melissa Lumish MD and Dr. William P. Tew of Team Ovary, Memorial Sloan Kettering Cancer Center 🔗bit.ly/OvarianCATopAd… Key updates: 🔸Mirvetuximab for PROC 🔸First data showing overall survival benefit for PARPi maintenance OncoAlert #gyncsm

Just published! "Top advances of the year: Ovarian Cancer" by Dr. <a href="/LumishMelissa/">Melissa Lumish MD</a> and Dr. William P. Tew of <a href="/TeamOvary_MSK/">Team Ovary, Memorial Sloan Kettering Cancer Center</a>

🔗bit.ly/OvarianCATopAd…

Key updates:
🔸Mirvetuximab for PROC 
🔸First data showing overall survival benefit for PARPi maintenance

<a href="/OncoAlert/">OncoAlert</a> 
#gyncsm
Melissa Lumish MD (@lumishmelissa) 's Twitter Profile Photo

Early onset GI cancers will be highlighted at ASCO #GI24 EO-EGC is rising along with CRC. Our results in JNCI show EO-EGC is: ⬆️gastric ⬆️diffuse type 🟰 stage/survival Much still unknown Fantastic collaboration Andrea Cercek Yelena Y. Janjigian MD Steve Maron Memorial Sloan Kettering Cancer Center

Early onset GI cancers will be highlighted at <a href="/ASCO/">ASCO</a> #GI24

EO-EGC is rising along with CRC. Our results in <a href="/JNCI_Now/">JNCI</a> show EO-EGC is:
⬆️gastric ⬆️diffuse type
đźź° stage/survival 
Much still unknown
Fantastic collaboration <a href="/AndreaCercek/">Andrea Cercek</a>  <a href="/YJanjigianMD/">Yelena Y. Janjigian MD</a> <a href="/SteveMaronMD/">Steve Maron</a> <a href="/MSKCancerCenter/">Memorial Sloan Kettering Cancer Center</a>
Sharlene Gill, MD, MPH, MBA, FASCO (@gillsharlene) 's Twitter Profile Photo

#GI24 ASCO Excellent Keynote by Kimmie Ng, MD, MPH highlighting early onset GI Cancers 👏 #CalltoAction 📌 specialized care pathways 📌 universal genetic testing 📌 public health aware 📌 ⬆️research OncoAlert OncoDaily Rachna Shroff, MD, MS, FASCO

#GI24 <a href="/ASCO/">ASCO</a> 
Excellent Keynote by <a href="/KimmieNgMD/">Kimmie Ng, MD, MPH</a> highlighting early onset GI Cancers 👏 
#CalltoAction
📌 specialized care pathways
📌 universal genetic testing
📌 public health aware
📌 ⬆️research
<a href="/OncoAlert/">OncoAlert</a> <a href="/oncodaily/">OncoDaily</a> 
<a href="/rachnatshroff/">Rachna Shroff, MD, MS, FASCO</a>
Lee M. Ocuin MD, FACS (@thenotorioushpb) 's Twitter Profile Photo

As we grow our #HAI pump program University Hospitals, we now offer this option to patients with colorectal liver metastases or intrahepatic cholangiocarcinoma in robotic-assisted fashion! Great application of the 🤖. EA2222 opening soon! Eva Selfridge COLONTOWN Cholangiocarcinoma Foundation ECOG-ACRIN Cancer Research Group

Brad Lander (@bradlander18) 's Twitter Profile Photo

Now published in JAMA Cardiology, we describe the ECG findings in WNBA players and highlight the importance of sport/sex-specific datasets. jamanetwork.com/journals/jamac… Significant findings are below:

Now published in <a href="/JAMACardio/">JAMA Cardiology</a>, we describe the ECG findings in <a href="/WNBA/">WNBA</a> players and highlight the importance of sport/sex-specific datasets. 

jamanetwork.com/journals/jamac…

Significant findings are below:
Memorial Sloan Kettering Cancer Center (@mskcancercenter) 's Twitter Profile Photo

Part of Karuna Ganesh’s conclusion during her research presentation on #colorectalcancer progression: “#CRC metastases span an expanded range of canonical intestinal and non-canonical states.” Learn more: bit.ly/3VPwJvF #AACR24

Part of <a href="/KarunaMDPhD/">Karuna Ganesh</a>’s conclusion during her research presentation on #colorectalcancer progression: “#CRC metastases span an expanded range of canonical intestinal and non-canonical states.” Learn more: bit.ly/3VPwJvF #AACR24
Memorial Sloan Kettering Cancer Center (@mskcancercenter) 's Twitter Profile Photo

Medical fellow Stefanie Gerstberger presents her research on how colibactin mutation signatures are associated with younger age of onset in #colorectalcancer during a Poster session at #AACR24. Learn more:bit.ly/3Jbuc7i

Medical fellow Stefanie Gerstberger presents her research on how colibactin mutation signatures are associated with younger age of onset in #colorectalcancer during a Poster session at #AACR24. Learn more:bit.ly/3Jbuc7i
Melissa Lumish MD (@lumishmelissa) 's Twitter Profile Photo

Grateful for ongoing mentorship from Karuna Ganesh and the opportunity to present early findings from our longitudinal study of #microbiome correlates of early age at onset and tumor sidedness in #CRC Memorial Sloan Kettering Cancer Center University Hospitals Case Comp Cancer Ctr

Grateful for ongoing mentorship from <a href="/KarunaMDPhD/">Karuna Ganesh</a> and the opportunity to present early findings from our longitudinal study of #microbiome correlates of early age at onset and tumor sidedness in #CRC <a href="/MSKCancerCenter/">Memorial Sloan Kettering Cancer Center</a> <a href="/UHhospitals/">University Hospitals</a> <a href="/caseccc/">Case Comp Cancer Ctr</a>
Melissa Lumish MD (@lumishmelissa) 's Twitter Profile Photo

Always inspiring to learn from Kimmie Ng, MD, MPH about ongoing efforts to dissect the drivers of #earlyonset #CRC including an understanding of the birth cohort effect and the need for cross-institution collaboration AACR Mary Beth Terry Yin Cao Case Comp Cancer Ctr

Always inspiring to learn from <a href="/KimmieNgMD/">Kimmie Ng, MD, MPH</a> about ongoing efforts to dissect the drivers of #earlyonset #CRC including an understanding of the birth cohort effect and the need for cross-institution collaboration <a href="/AACR/">AACR</a> <a href="/profmbtnyc/">Mary Beth Terry</a> <a href="/yincaoScD/">Yin Cao</a> <a href="/caseccc/">Case Comp Cancer Ctr</a>
NEJM (@nejm) 's Twitter Profile Photo

An analysis of published studies suggests that a longer duration of immune checkpoint inhibitor therapy is associated with a higher incidence of complete response among patients with mismatch repair–deficient cancers. Full correspondence: nej.md/3EXiEpe

An analysis of published studies suggests that a longer duration of immune checkpoint inhibitor therapy is associated with a higher incidence of complete response among patients with mismatch repair–deficient cancers. Full correspondence: nej.md/3EXiEpe
NEJM (@nejm) 's Twitter Profile Photo

Presented at #AACR25: Neoadjuvant PD-1 blockade with dostarlimab led to organ preservation in a high proportion of patients with early-stage mismatch repair–deficient tumors, with no compromise of surgical options. Full study results: nej.md/3EsWcoi  AACR

Presented at #AACR25:

Neoadjuvant PD-1 blockade with dostarlimab led to organ preservation in a high proportion of patients with early-stage mismatch repair–deficient tumors, with no compromise of surgical options. Full study results: nej.md/3EsWcoi  

<a href="/AACR/">AACR</a>
AACR (@aacr) 's Twitter Profile Photo

PD-1 immunotherapy can eliminate the need for surgery in patients with early-stage, DNA mismatch repair-deficient solid cancers, according to results presented by Andrea Cercek, MD: aacr.org/about-the-aacr… #AACR25 Andrea Cercek @MSK_DeptofMed Memorial Sloan Kettering Cancer Center

PD-1 immunotherapy can eliminate the need for surgery in patients with early-stage, DNA mismatch repair-deficient solid cancers, according to results presented by Andrea Cercek, MD: aacr.org/about-the-aacr…
#AACR25 <a href="/AndreaCercek/">Andrea Cercek</a> @MSK_DeptofMed <a href="/MSKCancerCenter/">Memorial Sloan Kettering Cancer Center</a>
Memorial Sloan Kettering Cancer Center (@mskcancercenter) 's Twitter Profile Photo

New research presented by MSK gastrointestinal medical oncologist Yelena Y. Janjigian MD at #AACR25 shows that a simple blood test can help doctors identify which patients are most likely to benefit from #immunotherapy after cancer surgery to remove tumors — potentially preventing the

New research presented by MSK gastrointestinal medical oncologist <a href="/YJanjigianMD/">Yelena Y. Janjigian MD</a> at #AACR25 shows that a simple blood test can help doctors identify which patients are most likely to benefit from #immunotherapy after cancer surgery to remove tumors — potentially preventing the